使用同种异体黑色素瘤肿瘤细胞裂解物疫苗Melacine的临床试验结果。

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

作者信息

Sondak Vernon K, Sosman Jeffrey A

机构信息

Division of Surgical Oncology, University of Michigan Health System, 3306 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932, USA.

出版信息

Semin Cancer Biol. 2003 Dec;13(6):409-15. doi: 10.1016/j.semcancer.2003.09.004.

DOI:10.1016/j.semcancer.2003.09.004

PMID:15001159

Abstract

The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

摘要

与黑色素瘤相关的蛋白质和碳水化合物的鉴定促使了特定抗原疫苗的研发。然而，源自全同种异体细胞的疫苗具有许多优势。Melacine是一种同种异基因黑色素瘤肿瘤细胞裂解物与免疫佐剂DETOX的组合。IV期黑色素瘤的I期和II期试验显示出低水平的抗肿瘤活性，但这种疫苗在辅助治疗方面最具前景。一项III期试验表明，Melacine对表达HLA I类抗原A2和/或HLA-C3的黑色素瘤患者亚组有生存益处。这一发现现在必须进行前瞻性确认。